| CAS | 129176-97-2 |
| Sequence | H-D-Lys(nicotinoyl)-Pro-β-(3-pyridyl)-Ala-Pro-3,4-dichloro-D-Phe-Asn-D-Trp-Phe-D-Trp-Leu-Nle-NH2 |
| Sequence Single | k(nicotinoyl)P-β-(3-pyridyl)AP-3,4-dichloro-fNwFwL-Nle-NH2 |
| Molecular Formula | C86H104Cl2N18O13 |
| Molecular Weight | 1668.79 |
| Synonyms | (D-Lys(nicotinoyl)1,β-(3-pyridyl)-Ala3,3,4-dichloro-D-Phe5,Asn6,D-Trp7.9,Nle11)-Substance P |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Description | Spantide II also called (D-Lys(nicotinoyl)1,β-(3-pyridyl)-Ala3,3,4-dichloro-D-Phe5,Asn6,D-Trp7.9,Nle11)-Substance P, an undecapeptide substance P (SP) analog, is a potent neurokinin-1 receptor (NK-1R) antagonist. Spantide II binds with NK-1R and blocks proinflammatory activities associated with SP. Spantide II can be used in the research of inflammatory skin disorders, such as psoriasis and contact dermatitis. Spantide II is even more potent as a substance P antagonist than spantide I and less effective in releasing histamine from mast cells. Of further advantage is the negligible neurotoxicity of spantide II. |
| References | 1. K+ channels as targets for specific immunomodulation. K.G.Chandy et al., Trends Pharmacol. Sci., 25, 280 (2004) 2. Antinociceptive and substance P antagonistic effects of intrathecally injected spantide II in rat: no signs of motor impairment or neurotoxicity. Z.Wiesenfeld-Hallin et al., Regul. Pept., 29, 1 (1990) 3. Comparison of spantide II and CP-96,345 for blockade of tachykinin-evoked contractions of smooth muscle. R.Hakanson et al., Biochem. Biophys. Res. Commun., 178, 297 (1991) 4. Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity. K.Folkers et al., Proc. Natl. Acad. Sci. USA, 87, 4833 (1990) 5. Spantide II, a novel tachykinin antagonist, and galanin inhibit plasma extravasation induced by antidromic C-fiber stimulation in rat hindpaw. Xu XJ, et al. Neuroscience. 1991;42(3):731-7. 6. In vitro and in vivo evaluation of topical formulations of spantide II. Kikwai L, et al. AAPS PharmSciTech. 2005 Oct 31;6(4):E565-72. 7. Percutaneous absorption and anti-inflammatory effect of a substance P receptor antagonist: spantide II. Babu RJ, et al. Pharm Res. 2004 Jan;21(1):108-13. |